Lava Therapeutics

LAVA Therapeutics is developing a proprietary bispecific antibody platform that can bind to γ-δT cells for the treatment of hematological and solid cancers. The company’s first-class immuno-oncology approach activates Vγ9Vδ2T cells after binding to membrane-expressed tumor targets. LAVA was founded in 2016 based on intellectual property from the Amsterdam University Medical Center.